[go: up one dir, main page]

GT200200235A - Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2 - Google Patents

Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2

Info

Publication number
GT200200235A
GT200200235A GT200200235A GT200200235A GT200200235A GT 200200235 A GT200200235 A GT 200200235A GT 200200235 A GT200200235 A GT 200200235A GT 200200235 A GT200200235 A GT 200200235A GT 200200235 A GT200200235 A GT 200200235A
Authority
GT
Guatemala
Prior art keywords
receiver
pharmaceutical compositions
procedures
selective agonists
manage selective
Prior art date
Application number
GT200200235A
Other languages
English (en)
Inventor
Francis Dumont
Jinyang Hong
Yesook Kim
Richard Wilker Korsmeyer
Mei Li
Vishwas Madhav Paralkar
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GT200200235A publication Critical patent/GT200200235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS DE AGONISTAS SELECTIVOS DEL RECEPTOR EP2 SIN LOS EFECTOS SECUNDARIOS OBJETABLES DE LA PEG2 POR LO QUE SON DE UTILIDAD PARA POTENCIAR LA REPARACION Y LA CURACION DE LOS HUESOS Y PARA RESTAURAR O AUMENTAR LA MASA OSEA EN VERTEBRADOS, PARTICULARMENTE EN MAMIFEROS.
GT200200235A 2001-11-30 2002-11-21 Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2 GT200200235A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33515601P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
GT200200235A true GT200200235A (es) 2003-06-25

Family

ID=23310510

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200235A GT200200235A (es) 2001-11-30 2002-11-21 Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2

Country Status (24)

Country Link
US (1) US20030166631A1 (es)
EP (1) EP1448182A1 (es)
JP (1) JP2005513030A (es)
KR (1) KR20040063981A (es)
CN (1) CN1599605A (es)
AR (1) AR037593A1 (es)
AU (1) AU2002348948A1 (es)
BR (1) BR0214614A (es)
CA (1) CA2468494A1 (es)
GT (1) GT200200235A (es)
HN (1) HN2002000336A (es)
IL (1) IL161834A0 (es)
MX (1) MXPA04003689A (es)
NO (1) NO20042272L (es)
NZ (1) NZ532209A (es)
PA (1) PA8559601A1 (es)
PE (1) PE20030660A1 (es)
PL (1) PL370914A1 (es)
RU (1) RU2004116318A (es)
SV (1) SV2004001417A (es)
TW (1) TW200300342A (es)
UY (1) UY27556A1 (es)
WO (1) WO2003045371A1 (es)
ZA (1) ZA200402795B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US20070270489A1 (en) * 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
EP1723132A1 (en) * 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
JP2008507477A (ja) * 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
WO2007017687A2 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
AU2007223981B2 (en) * 2006-03-07 2011-12-01 Osteoscreen Ip, Llc HMG Co-A reductase inhibitor enhancement of bone and cartilage
EP2059507B1 (en) 2006-07-28 2013-03-20 Pfizer Products Inc. Ep2 agonist
EP2094273B1 (en) 2006-11-16 2013-03-06 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
WO2009025793A2 (en) * 2007-08-21 2009-02-26 Senomyx, Inc. Human t2r bitterness receptors and uses thereof
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
FR3034678A1 (fr) * 2015-04-07 2016-10-14 Geocorail Dispositif, procede et compose pour la reconstruction osseuse d'un vertebre.
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
CN108713059A (zh) * 2016-02-12 2018-10-26 蓝鸟生物公司 Vcn增强子组合物和其使用方法
WO2021163400A1 (en) 2020-02-12 2021-08-19 Cytoagents, Inc. Compositions and methods for treating coronavirus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4789663A (en) * 1984-07-06 1988-12-06 Collagen Corporation Methods of bone repair using collagen
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
WO1998027976A1 (en) * 1996-12-20 1998-07-02 Pfizer Inc. Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists

Also Published As

Publication number Publication date
BR0214614A (pt) 2004-09-14
AU2002348948A1 (en) 2003-06-10
RU2004116318A (ru) 2005-03-27
UY27556A1 (es) 2003-06-30
KR20040063981A (ko) 2004-07-15
HN2002000336A (es) 2003-02-10
SV2004001417A (es) 2004-02-24
EP1448182A1 (en) 2004-08-25
JP2005513030A (ja) 2005-05-12
CA2468494A1 (en) 2003-06-05
WO2003045371A1 (en) 2003-06-05
NZ532209A (en) 2007-05-31
US20030166631A1 (en) 2003-09-04
CN1599605A (zh) 2005-03-23
MXPA04003689A (es) 2004-07-23
TW200300342A (en) 2003-06-01
PL370914A1 (en) 2005-06-13
NO20042272L (no) 2004-07-28
PA8559601A1 (es) 2003-07-28
PE20030660A1 (es) 2003-08-04
AR037593A1 (es) 2004-11-17
IL161834A0 (en) 2005-11-20
ZA200402795B (en) 2005-04-13

Similar Documents

Publication Publication Date Title
GT200200235A (es) Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
HN2002000266A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
GT200200133A (es) Formulaciones de latex libres de aceleradores, metodos para hacer dichas formulaciones y articulos hechos de los mismos
EE200300524A (et) Ühendid, mis on CB2-retseptori agonistid, neid sisaldavad ravimkoostised ja nimetatud ühendite kasutamine ravis
AR023129A1 (es) Composiciones para mejorar la fertilidad
HN2004000538A (es) "PIRIDO[ 2,3-d ] PIRIMIDINA-2,4-DIAMINAS COMO-INHIBIDORES DE PDE 2"
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
PA8452701A1 (es) Agonistas de prostaglandinas
BR0210268A (pt) Absorvente labial
ECSP044981A (es) Composicion oftalmica que comprende ascomicina
UY37813A (es) Derivados de pirrolopiridina sustituidos
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
BR0207543A (pt) Quinolinona tricìclica e quinolina tricìclica como compostos moduladores de receptor de androgênio
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
BR0209440A (pt) Sulfonamidas
AR028730A1 (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxis de la obesidad y utilizacion de dichos compuestos
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
HN1999000196A (es) Derivados de indol
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
HN2002000348A (es) Combinacion farmaceutica
ES2181396T3 (es) Inhibicion de la apoptosis independiente de cd95 en el sida.